Print    

Home Page / Resources / Case Studies ...

Case Studies

Small Company expertise & capacity - P450 Inhibition Assay

The Situation: A small pharmaceutical company did not have the in-house MS analysis capacity to routinely analyze P450 inhibition screens. They wanted a cost effective out-sourcing solution that integrated seamlessly with their current workflow and also provided rapid data turnaround to assure steady progress in their drug discovery programs. Seamless integration for this client meant that they retained full control of their assay protocols and compound identities as well as flexibility in assay plate format.

Addressing the Challenges: Could the RapidFire service be used to analyze plates from their current assays without any further modifications to their protocols? The RapidFire team worked with the client to provide an evaluation of the RapidFire CYP inhibition service that would assure them that this service could provide consistent data rapidly and integrate seamlessly into their current workflow.

Results: The client continues to utilize the BIOCIUS RapidFire CYP Inhibition Service on a routine basis by sending quenched assay samples to BIOCIUS for analysis. Data from P450 inhibition assays is sent back to the client within 3 days of receipt and often faster. By utilizing this analysis service the client was able to get the data they need while fully controlling assay protocols and preparation, compound identity, and plate formats without delays in their drug discovery programs.

Delivering an Ultra High-throughput P450 Inhibition Assay

The Situation: A large pharmaceutical company was consolidating global P450 inhibition screening operations to a single location. This single facility now needed to meet the requirements of quickly and efficiently performing these assays at a capacity several fold higher than their current abilities without significantly altering their current assay protocols including the acquiring of data from full IC50 curves for several CYP isoforms. The global capacity analysis needs for this assay was estimated to be in excess of 500,000 samples per year.

Addressing the Challenges: The RapidFire team worked with the client to customize the existing RapidFire CYP inhibition analysis methods to meet their requirements. The new methods not only needed to be quick and efficient, but they also needed to measure up to an extensive validation of cross platform equivalence (in-house data vs. RapidFire) evaluated by analyzing a data set containing tens of thousands of wells over a time period of several months.

Results: The RapidFire platform and newly developed methods successfully met the client's high expectations by increasing analysis speed and sample volume capacity without sacrificing data integrity. Initially the client utilized the BIOCIUS RapidFire CYP Inhibition Service by sending quenched assay samples in high volume to BIOCIUS for analysis. After a period of time the client worked closely with the RapidFire team to install a RapidFire MS system in their facility and transition the sample analysis in-house.

BIOCIUS. Faster Answers.

RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,